乳腺癌随访及伴随疾病全方位管理指南

In recent years, with the emphasis on breast cancer screening and the improvement of breast cancer diagnosis and treatment, five⁃year survival rate and the overall survival time of breast cancer patients have been significantly improved in China. The adverse events caused by patients′ age, changes in hormone levels or anti⁃cancer treatment during follow⁃up have become new challenges in the management of patients with breast cancer, not only affecting the quality of life, but also impacting disease recurrence and death. The management of patients should not be restricted to the diagnosis and treatment of breast cancer, but to a most comprehensive management. This could improve the therapeutic efficacy of anti⁃cancer treatment and the quality of life of patients. Based on the current landscape of treatment and follow⁃up of breast cancer patients in China, the experts committee drafted the “Comprehensive Management Guideline for Breast Cancer Follow⁃up and Concomitant Diseases” according to the literature and relevant guidelines. This guideline is composed of four parts: path diagram, follow⁃up management, concomitant diseases and adverse events management. It aims to standardize the long⁃term follow⁃up of breast cancer patients, guide clinicians to deal with the concomitant diseases and adverse events, and further improve the prognosis and quality of life of breast cancer patients in China.